JPH0319228B2 - - Google Patents
Info
- Publication number
- JPH0319228B2 JPH0319228B2 JP58058800A JP5880083A JPH0319228B2 JP H0319228 B2 JPH0319228 B2 JP H0319228B2 JP 58058800 A JP58058800 A JP 58058800A JP 5880083 A JP5880083 A JP 5880083A JP H0319228 B2 JPH0319228 B2 JP H0319228B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- pharmaceutically acceptable
- acid addition
- acceptable acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 17
- -1 alkyl radical Chemical class 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- AJMYPKLESMBNOY-UHFFFAOYSA-N n,n-dimethyl-2-(3-phenylquinolin-2-yl)oxyethanamine Chemical compound CN(C)CCOC1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 AJMYPKLESMBNOY-UHFFFAOYSA-N 0.000 claims description 5
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 5
- 239000012312 sodium hydride Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 230000008485 antagonism Effects 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 239000003701 inert diluent Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- WMSMYWZAPQVNTQ-UHFFFAOYSA-N n,n-diethyl-2-(3-phenylquinolin-2-yl)oxyethanamine Chemical compound CCN(CC)CCOC1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 WMSMYWZAPQVNTQ-UHFFFAOYSA-N 0.000 claims 3
- FSEXLNMNADBYJU-UHFFFAOYSA-N 2-phenylquinoline Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=N1 FSEXLNMNADBYJU-UHFFFAOYSA-N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000003420 antiserotonin agent Substances 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical compound [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 9
- 239000003208 petroleum Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960001582 fenfluramine Drugs 0.000 description 5
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 5
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- LFARBJHRSSLIGX-UHFFFAOYSA-N 2-chloro-3-phenylquinoline Chemical compound ClC1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 LFARBJHRSSLIGX-UHFFFAOYSA-N 0.000 description 3
- LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- KRZIUCWIMUOCTD-UHFFFAOYSA-N 2-chloro-3-(4-fluorophenyl)quinoline Chemical compound C1=CC(F)=CC=C1C1=CC2=CC=CC=C2N=C1Cl KRZIUCWIMUOCTD-UHFFFAOYSA-N 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 206010020843 Hyperthermia Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 235000011167 hydrochloric acid Nutrition 0.000 description 2
- 230000036031 hyperthermia Effects 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- JBSUQZRJPWKBTP-UHFFFAOYSA-N n,n-dimethyl-2-(3-phenylquinolin-2-yl)oxyethanamine;hydrochloride Chemical compound Cl.CN(C)CCOC1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 JBSUQZRJPWKBTP-UHFFFAOYSA-N 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 239000004089 psychotropic agent Substances 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229950001675 spiperone Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 2
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- XRIBIDPMFSLGFS-UHFFFAOYSA-N 2-(dimethylamino)-2-methylpropan-1-ol Chemical compound CN(C)C(C)(C)CO XRIBIDPMFSLGFS-UHFFFAOYSA-N 0.000 description 1
- PBKGYWLWIJLDGZ-UHFFFAOYSA-N 2-(dimethylamino)propan-1-ol Chemical compound OCC(C)N(C)C PBKGYWLWIJLDGZ-UHFFFAOYSA-N 0.000 description 1
- RXLXNLJLVDSXCG-UHFFFAOYSA-N 2-[3-(4-fluorophenyl)quinolin-2-yl]oxy-n,n-dimethylethanamine;hydrochloride Chemical compound Cl.CN(C)CCOC1=NC2=CC=CC=C2C=C1C1=CC=C(F)C=C1 RXLXNLJLVDSXCG-UHFFFAOYSA-N 0.000 description 1
- CBICQVIAVZYAIA-UHFFFAOYSA-N 2-chloro-3-propan-2-ylquinoline Chemical compound C1=CC=C2N=C(Cl)C(C(C)C)=CC2=C1 CBICQVIAVZYAIA-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- PYSGFFTXMUWEOT-UHFFFAOYSA-N 3-(dimethylamino)propan-1-ol Chemical compound CN(C)CCCO PYSGFFTXMUWEOT-UHFFFAOYSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 doseâresponse relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- AYYQJBQRBDOMDE-UHFFFAOYSA-N n,n-dimethyl-1-(3-phenylquinolin-2-yl)oxypropan-2-amine;hydrochloride Chemical compound Cl.CN(C)C(C)COC1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 AYYQJBQRBDOMDE-UHFFFAOYSA-N 0.000 description 1
- PEFMYFJTZDKFMJ-UHFFFAOYSA-N n,n-dimethyl-2-(3-propan-2-ylquinolin-2-yl)oxyethanamine;hydrochloride Chemical compound Cl.C1=CC=C2N=C(OCCN(C)C)C(C(C)C)=CC2=C1 PEFMYFJTZDKFMJ-UHFFFAOYSA-N 0.000 description 1
- OIXUOGYTXNJEAL-UHFFFAOYSA-N n,n-dimethyl-3-(3-phenylquinolin-2-yl)oxypropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCOC1=NC2=CC=CC=C2C=C1C1=CC=CC=C1 OIXUOGYTXNJEAL-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
ãçºæã®è©³çŽ°ãªèª¬æã
æ¬çºæã¯ãæž©è¡åç©äžã®ïŒâããããã·ããªã
ã¿ãã³æ®å質ãšããŠæŽ»æ§ã§ãããããªã³èªå°äœã«
é¢ããã
ã¿ãã³æ®å質ãšããŠæŽ»æ§ã§ãããããªã³èªå°äœã«
é¢ããã
ååç©ïŒâïŒïŒâãžã¡ãã«ã¢ãããšããã·ïŒâïŒ
âããšãã«ãããªã³ã¯ç±³åœç¹èš±ç¬¬1860286å·æ现
æžã«èšèŒãããŠãããã€è§£ç±äœçšãæãããšè¿°ã¹
ãããŠããããããåœæ¥è ã«ãšã€ãŠãã®åã®åå
ç©ãïŒâããããã·ããªãã¿ãã³ïŒïŒâHTïŒæ®
æ質ã§ããããšãäºæž¬ããããšã¯ã§ããªãã€ãã
âããšãã«ãããªã³ã¯ç±³åœç¹èš±ç¬¬1860286å·æ现
æžã«èšèŒãããŠãããã€è§£ç±äœçšãæãããšè¿°ã¹
ãããŠããããããåœæ¥è ã«ãšã€ãŠãã®åã®åå
ç©ãïŒâããããã·ããªãã¿ãã³ïŒïŒâHTïŒæ®
æ質ã§ããããšãäºæž¬ããããšã¯ã§ããªãã€ãã
æ¬çºæã«ããïŒâïŒïŒâãžã¡ãã«ã¢ãããšãã
ã·ïŒâïŒâããšãã«ãããªã³åã³ããã®è£œè¬åŠç
ã«èš±å®¹ãããé žä»å å¡©ãé€ããŠãåŒïŒ ãåŒäž ã¯ã¡ãã«åºïŒåã¯ïŒåã«ãã眮æãããŠããŠ
ãããâïŒCH2ïŒ2âåºãåã¯âïŒCH2ïŒ3âåºãè¡šã
ãã R1ã¯ïœâãã€ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºã
ã·ã¯ããããã«åºãåã¯ããã²ã³åååã¯C1ã4â
ã¢ã«ã³ãã·åºã«ãã眮æãããŠããŠãããããšã
ã«åºãè¡šããã R2åã³R3ã¯åããåã¯ç°ãªã€ãŠããŠãããã¡
ãã«åºåã¯ãšãã«åºãè¡šãããã®ãããªã³èªå°äœ
åã³ãã®è£œè¬åŠçã«èš±å®¹ãããé žä»å å¡©ãåŸãã
ãã
ã·ïŒâïŒâããšãã«ãããªã³åã³ããã®è£œè¬åŠç
ã«èš±å®¹ãããé žä»å å¡©ãé€ããŠãåŒïŒ ãåŒäž ã¯ã¡ãã«åºïŒåã¯ïŒåã«ãã眮æãããŠããŠ
ãããâïŒCH2ïŒ2âåºãåã¯âïŒCH2ïŒ3âåºãè¡šã
ãã R1ã¯ïœâãã€ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºã
ã·ã¯ããããã«åºãåã¯ããã²ã³åååã¯C1ã4â
ã¢ã«ã³ãã·åºã«ãã眮æãããŠããŠãããããšã
ã«åºãè¡šããã R2åã³R3ã¯åããåã¯ç°ãªã€ãŠããŠãããã¡
ãã«åºåã¯ãšãã«åºãè¡šãããã®ãããªã³èªå°äœ
åã³ãã®è£œè¬åŠçã«èš±å®¹ãããé žä»å å¡©ãåŸãã
ãã
æ¬çºæã®ããã€ãã®ååç©ã¯å°ãªããšãïŒåã®
äžæŽççŽ ååãå«æããäŸãã°ïŒ¡ãã¡ãã«åºãæ
ããâïŒCH2ïŒ2âåºãè¡šããå Žåã§ãããå°ãªã
ãšãïŒåã®äžæŽççŽ ååãå«æãããã®ãããªå
åç©ã®ã©ã»ã圢ã¯åžžæ³ã§ãã®å åŠæŽ»æ§ç°æ§äœã«å
å²ããããšãã§ãããæ¬çºæã«ããååç©ãïŒâ
HTæ®æäœã§ãã(a)ã©ã»ã圢ã®åŒã®ååç©åã³
(b)ãã®å åŠç°æ§äœãå å«ããããšã¯æããã§ã
ãã
äžæŽççŽ ååãå«æããäŸãã°ïŒ¡ãã¡ãã«åºãæ
ããâïŒCH2ïŒ2âåºãè¡šããå Žåã§ãããå°ãªã
ãšãïŒåã®äžæŽççŽ ååãå«æãããã®ãããªå
åç©ã®ã©ã»ã圢ã¯åžžæ³ã§ãã®å åŠæŽ»æ§ç°æ§äœã«å
å²ããããšãã§ãããæ¬çºæã«ããååç©ãïŒâ
HTæ®æäœã§ãã(a)ã©ã»ã圢ã®åŒã®ååç©åã³
(b)ãã®å åŠç°æ§äœãå å«ããããšã¯æããã§ã
ãã
äŸãã°ãã¯ïŒïŒïŒâãšãã¬ã³ãïŒïŒïŒâãã
ãã¬ã³ãïŒïŒïŒâãããã¬ã³ãïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãšãã¬ã³ãïŒïŒïŒâãžã¡ãã«âïŒïŒïŒ
âãšãã¬ã³åã¯ïŒïŒïŒâãããã¬ã³åºã§ãã€ãŠã
ãã
ãã¬ã³ãïŒïŒïŒâãããã¬ã³ãïŒïŒïŒâãžã¡ãã«
âïŒïŒïŒâãšãã¬ã³ãïŒïŒïŒâãžã¡ãã«âïŒïŒïŒ
âãšãã¬ã³åã¯ïŒïŒïŒâãããã¬ã³åºã§ãã€ãŠã
ãã
äŸãã°ãR1ã¯ïœâãããã«ãã€ãœãããã«ã
ïœâããã«ãïœâããã«åã¯ã·ã¯ããããã«åºã§
ãã€ãŠãããäŸãã°ãR1ã¯å Žåã«ããåŒçŽ ãå¡©
çŽ åã¯èçŽ ååãããã¯C1ã2âã¢ã«ã³ãã·åºãäŸ
ãã°ã¡ããã·åºã«ãã眮æãããŠããŠããããšã
ã«åºã§ãã€ãŠããã
ïœâããã«ãïœâããã«åã¯ã·ã¯ããããã«åºã§
ãã€ãŠãããäŸãã°ãR1ã¯å Žåã«ããåŒçŽ ãå¡©
çŽ åã¯èçŽ ååãããã¯C1ã2âã¢ã«ã³ãã·åºãäŸ
ãã°ã¡ããã·åºã«ãã眮æãããŠããŠããããšã
ã«åºã§ãã€ãŠããã
æ¬çºæã®ïŒå®æœåœ¢ã¯ããå Žåã«ããã¡ãã«åº
ïŒåã¯ïŒåã«ãã眮æãããŠããŠããâïŒCH2ïŒ2
âåºãåã¯âïŒCH2ïŒ3âåºã§ãããR1ã¯ïœâãã€
ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºãè¡šãããåã¯ã
ãšãã«ãããã²ãããšãã«åã¯C1ã2âã¢ã«ã³ãã·
ããšãã«åºãè¡šãããã€R2åã³R3ãã¡ãã«åºã
è¡šããåŒã®ãããªã³èªå°äœåã³ãã®è£œè¬çã«èš±
容ãããé žä»å å¡©ãå å«ããã
ïŒåã¯ïŒåã«ãã眮æãããŠããŠããâïŒCH2ïŒ2
âåºãåã¯âïŒCH2ïŒ3âåºã§ãããR1ã¯ïœâãã€
ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºãè¡šãããåã¯ã
ãšãã«ãããã²ãããšãã«åã¯C1ã2âã¢ã«ã³ãã·
ããšãã«åºãè¡šãããã€R2åã³R3ãã¡ãã«åºã
è¡šããåŒã®ãããªã³èªå°äœåã³ãã®è£œè¬çã«èš±
容ãããé žä»å å¡©ãå å«ããã
æ¬çºæã®å¥œé©ãªå¡©ã¯è£œè¬åŠçã«èš±å®¹ãããã¢ã
ãªã³ãäžããç¡æ©é žåã¯ææ©é žãäŸãã°å¡©é žããª
ã³é žãã¯ãšã³é žãå®æ¯éŠé žãé ç³é žåã¯ã³ãã¯é ž
ããèªå°ãããã
ãªã³ãäžããç¡æ©é žåã¯ææ©é žãäŸãã°å¡©é žããª
ã³é žãã¯ãšã³é žãå®æ¯éŠé žãé ç³é žåã¯ã³ãã¯é ž
ããèªå°ãããã
æ¬çºæã®åªããååç©ã¯ïŒâïŒïŒâãžã¡ãã«ã¢
ãããšããã·ïŒâïŒâããšãã«ãããªã³åã³è£œè¬
çã«èš±å®¹ããããã®é žä»å å¡©ãäŸãã°ãããã¯ã
ãªãã§ããã
ãããšããã·ïŒâïŒâããšãã«ãããªã³åã³è£œè¬
çã«èš±å®¹ããããã®é žä»å å¡©ãäŸãã°ãããã¯ã
ãªãã§ããã
æ¬çºæã®ååç©ãåã³æ¬çºææ¹æ³ã§åºçºç©è³ªãš
ããŠäœ¿ãããååç©ã¯ååŠçé¡çžååç©ã®çæã«
é¢ããŠç¥ãããŠããæ¹æ³ã«ããåŸããããæ¬çºæ
æ¹æ³ã§åºçºç©è³ªãšããŠäœ¿ãããäžæŽççŽ ååå°ãª
ããšãïŒåãå«æããååç©ã¯ã©ã»ã圢ã§åã¯å
åŠæŽ»æ§åœ¢ã§äœ¿çšããããšãã§ããã
ããŠäœ¿ãããååç©ã¯ååŠçé¡çžååç©ã®çæã«
é¢ããŠç¥ãããŠããæ¹æ³ã«ããåŸããããæ¬çºæ
æ¹æ³ã§åºçºç©è³ªãšããŠäœ¿ãããäžæŽççŽ ååå°ãª
ããšãïŒåãå«æããååç©ã¯ã©ã»ã圢ã§åã¯å
åŠæŽ»æ§åœ¢ã§äœ¿çšããããšãã§ããã
æ¬çºæã«ãããïŒâïŒïŒâãžãšãã«ã¢ãããšã
ãã·ïŒâïŒâããšãã«ãããªã³åã³ãã®è£œè¬åŠç
ã«èš±å®¹ãããé žä»å å¡©ãé€ããŠïŒ¡ãR1ãR2åã³
R3ãåèšã®ãã®ãè¡šããåŒã®ååç©åã³è£œè¬
åŠçã«èš±å®¹ããããã®é žä»å å¡©ã®è£œæ³ãåŸããã
ããã¯åŒïŒ ãåŒäžHalã¯ããã²ã³ååãè¡šãããã€R1ã¯å
èšã®ãã®ãè¡šãããã®ååç©ãåŒïŒ HOââNR2R3 ïŒïŒ ãåŒäžïŒ¡ãR2åã³R3ã¯åèšã®ãã®ãè¡šããã
ã®ååç©åã¯ãã®é žä»å å¡©ãšé žçµåå€ã®ååšã«ã
ããŠåå¿ãããããšãå å«ããã
ãã·ïŒâïŒâããšãã«ãããªã³åã³ãã®è£œè¬åŠç
ã«èš±å®¹ãããé žä»å å¡©ãé€ããŠïŒ¡ãR1ãR2åã³
R3ãåèšã®ãã®ãè¡šããåŒã®ååç©åã³è£œè¬
åŠçã«èš±å®¹ããããã®é žä»å å¡©ã®è£œæ³ãåŸããã
ããã¯åŒïŒ ãåŒäžHalã¯ããã²ã³ååãè¡šãããã€R1ã¯å
èšã®ãã®ãè¡šãããã®ååç©ãåŒïŒ HOââNR2R3 ïŒïŒ ãåŒäžïŒ¡ãR2åã³R3ã¯åèšã®ãã®ãè¡šããã
ã®ååç©åã¯ãã®é žä»å å¡©ãšé žçµåå€ã®ååšã«ã
ããŠåå¿ãããããšãå å«ããã
äŸãã°ãHalã¯å¡©çŽ åã¯èçŽ ååãè¡šãããŠã
ããäŸãã°åŒã®ååç©ã®å¡©ã¯ç¡æ©é žãäŸãã°ã
ãã²ã³åæ°ŽçŽ é žãäŸãã°å¡©é žããèªå°ãããå¡©ã§
ãã€ãŠãããäŸãã°ãé žçµåå€ã¯æ°ŽçŽ åãããªãŠ
ã ã§ãã€ãŠããããã®åå¿ã¯å¥œé©ãªææ©æº¶å€ãäŸ
ãã°ãžã¡ãã«ãã«ã ã¢ããäžã§è¡ãªãããšãã§
ãããã€å Žåã«ããç±ã®é©çšã«ããä¿é²åã¯å®çµ
ãããããšãã§ããã
ããäŸãã°åŒã®ååç©ã®å¡©ã¯ç¡æ©é žãäŸãã°ã
ãã²ã³åæ°ŽçŽ é žãäŸãã°å¡©é žããèªå°ãããå¡©ã§
ãã€ãŠãããäŸãã°ãé žçµåå€ã¯æ°ŽçŽ åãããªãŠ
ã ã§ãã€ãŠããããã®åå¿ã¯å¥œé©ãªææ©æº¶å€ãäŸ
ãã°ãžã¡ãã«ãã«ã ã¢ããäžã§è¡ãªãããšãã§
ãããã€å Žåã«ããç±ã®é©çšã«ããä¿é²åã¯å®çµ
ãããããšãã§ããã
ïŒâHTæ®æ質ãšããŠã®æ¬çºæã®ååç©ã®äœçš
ã¯æ¬¡ã®è©Šéšã§æããã«ããïŒ (1) è©Šéšç®¡å ïŒâHTå容äœçµå (a) äžéæ°ŽçŽ åïŒâããããã·ããªãã¿ãã³
ïŒã3HãïŒâHTïŒã®çµå ããã¯ãäžå€®ïŒâHT1å容äœãâMolecular
Pharmacologyâã16å·»ã687é ïŒ1979幎ïŒãã«å¯Ÿ
ããè©Šéšååç©ã®èŠªåæ§ã«ã€ããŠã®è©Šéšç®¡å è©Šéš
ã§ããããã®ååç©ããã©ããã®è³çµç¹ããã®ã·
ããããœãŒã æšæ¬ã®å容äœéšäœããã3HãïŒâ
HTã眮æãããã®èœåã«ã€ããŠè©Šéšããã該å
åç©3ÎŒgïŒmlã§è©Šéšããç¹ç°ççµåã30ïŒ ããå€
ãæå¶ããå Žåã«ããã掻æ§ã§ãããšèªããã
ããåœè©²ååç©ããã®å容äœã«å¯Ÿãã絶察å¹åã
確å®ããæ¿åºŠç¯å²ã§è©Šéšããããã®çµæãpI50å€
ã§è¡šããããã®pI50ã¯ç¹ç°çã«çµåããŠãã
ã3HãïŒâTHã®50ïŒ ã眮æããã®ã«å¿ èŠãªåå
ç©ã®æ¿åºŠã®âlog10ã§ããã
ã¯æ¬¡ã®è©Šéšã§æããã«ããïŒ (1) è©Šéšç®¡å ïŒâHTå容äœçµå (a) äžéæ°ŽçŽ åïŒâããããã·ããªãã¿ãã³
ïŒã3HãïŒâHTïŒã®çµå ããã¯ãäžå€®ïŒâHT1å容äœãâMolecular
Pharmacologyâã16å·»ã687é ïŒ1979幎ïŒãã«å¯Ÿ
ããè©Šéšååç©ã®èŠªåæ§ã«ã€ããŠã®è©Šéšç®¡å è©Šéš
ã§ããããã®ååç©ããã©ããã®è³çµç¹ããã®ã·
ããããœãŒã æšæ¬ã®å容äœéšäœããã3HãïŒâ
HTã眮æãããã®èœåã«ã€ããŠè©Šéšããã該å
åç©3ÎŒgïŒmlã§è©Šéšããç¹ç°ççµåã30ïŒ ããå€
ãæå¶ããå Žåã«ããã掻æ§ã§ãããšèªããã
ããåœè©²ååç©ããã®å容äœã«å¯Ÿãã絶察å¹åã
確å®ããæ¿åºŠç¯å²ã§è©Šéšããããã®çµæãpI50å€
ã§è¡šããããã®pI50ã¯ç¹ç°çã«çµåããŠãã
ã3HãïŒâTHã®50ïŒ ã眮æããã®ã«å¿ èŠãªåå
ç©ã®æ¿åºŠã®âlog10ã§ããã
(b) äžéæ°ŽçŽ åã¹ããããªããŒã«ïŒã3Hãã¹ãã
ããªããŒã«ïŒã®çµå ããã¯ãäžå€®ïŒâHT2å容äœãâMolecular
Pharmacologyâã16å·»ã687é ïŒ1979幎ïŒãã«å¯Ÿ
ããè©Šéšååç©ã®èŠªåæ§ã«ã€ããŠã®è©Šéšç®¡å è©Šéš
ã§ããããã®ååç©ããã©ããã®è³ç®è³ªããã®ã·
ããããœãŒã æšæ¬ã®å容äœããã3Hãã¹ããã
ãªããŒã«ã眮æãããã®èœåã«ã€ããŠè©Šéšããã
該ååç©3ÎŒgïŒmlã§è©Šéšããç¹ç°ççµåã30ïŒ ã
ãå€ãæå¶ããå Žåã«ããã掻æ§ã§ãããšèªãã
ãããåœè©²ååç©ãåèšã®ã3HãïŒâHTçµåã«
ã€ããŠèšèŒãããããªæ¿åºŠç¯å²ã§è©Šéšãããçµæ
ã¯pI50å€ãšããŠè¡šããããã®pI50ã¯ç¹ç°ççµåã®
ã3Hãã¹ããããªããŒã«ã®50ïŒ ã眮æããã®ã«å¿
èŠãªååç©ã®æ¿åºŠã®âlog10ã§ããã
ããªããŒã«ïŒã®çµå ããã¯ãäžå€®ïŒâHT2å容äœãâMolecular
Pharmacologyâã16å·»ã687é ïŒ1979幎ïŒãã«å¯Ÿ
ããè©Šéšååç©ã®èŠªåæ§ã«ã€ããŠã®è©Šéšç®¡å è©Šéš
ã§ããããã®ååç©ããã©ããã®è³ç®è³ªããã®ã·
ããããœãŒã æšæ¬ã®å容äœããã3Hãã¹ããã
ãªããŒã«ã眮æãããã®èœåã«ã€ããŠè©Šéšããã
該ååç©3ÎŒgïŒmlã§è©Šéšããç¹ç°ççµåã30ïŒ ã
ãå€ãæå¶ããå Žåã«ããã掻æ§ã§ãããšèªãã
ãããåœè©²ååç©ãåèšã®ã3HãïŒâHTçµåã«
ã€ããŠèšèŒãããããªæ¿åºŠç¯å²ã§è©Šéšãããçµæ
ã¯pI50å€ãšããŠè¡šããããã®pI50ã¯ç¹ç°ççµåã®
ã3Hãã¹ããããªããŒã«ã®50ïŒ ã眮æããã®ã«å¿
èŠãªååç©ã®æ¿åºŠã®âlog10ã§ããã
(2) ããŠã¹ã«ãããŠïŒâããããã·ããªãããã¢
ã³ïŒïŒâHTPïŒã«ããèªçºãããé éšæ£çž®ã®
é»æ¢ ããã¯ãäžå€®ïŒâHTå容äœã§ã®äœçšæ§ã«ã€ã
ãŠã®çäœå è©Šéšã§ããããã®è©Šéšã¯ïŒâHTã®å
é§ç©è³ªãã€ãŸãïŒâHTPãããŠã¹ã«æäžããã
ãšããã®çµæè³ã®äžã§çããé«ã¬ãã«ã®ïŒâHT
ãïŒâHTPã®æäžåŸã«äžå®æéèŠãããé éšå
ã³è³ã®èªçºæ£çž®ã®åå ã§ãããšèŠãªãããããã¹
ãŠã®å ¬ç¥ã®äžå€®ã«äœçšããïŒâHTæ®æ質ã¯çšé
ã«çžå¿ããŠæ£çž®å¿çãé»æ¢ããã
ã³ïŒïŒâHTPïŒã«ããèªçºãããé éšæ£çž®ã®
é»æ¢ ããã¯ãäžå€®ïŒâHTå容äœã§ã®äœçšæ§ã«ã€ã
ãŠã®çäœå è©Šéšã§ããããã®è©Šéšã¯ïŒâHTã®å
é§ç©è³ªãã€ãŸãïŒâHTPãããŠã¹ã«æäžããã
ãšããã®çµæè³ã®äžã§çããé«ã¬ãã«ã®ïŒâHT
ãïŒâHTPã®æäžåŸã«äžå®æéèŠãããé éšå
ã³è³ã®èªçºæ£çž®ã®åå ã§ãããšèŠãªãããããã¹
ãŠã®å ¬ç¥ã®äžå€®ã«äœçšããïŒâHTæ®æ質ã¯çšé
ã«çžå¿ããŠæ£çž®å¿çãé»æ¢ããã
è©Šéšäžã®æ¬ååç©ã®çšéç¯å²ãïŒâHTP300
mgïŒKgãè ¹è å æ³šå ¥ãã15ååã«éããŠã¹ïŒå¹³å
äœé18ã20gïŒïŒçŸ€ã«ãããŠïŒã«è ¹è å æäžã
ãããã®åŸã15ååŸã«ããŠã¹ãé éšæ£çž®ã«é¢ããŠ
芳å¯ãããã€ãã®çµæãID50å€ãšããŠè¡šãããäŸ
ãã°é®éã«ããå¿çã®ç¹ç°çæå¶ã¯ãè³ã®è§ŠèŠç
åºæ¿ã«å¯Ÿããè³ç¿Œåå°ã®ååšåã¯äžååšã®æž¬å®ã«
ããã°æé€ãããŠããªãã
mgïŒKgãè ¹è å æ³šå ¥ãã15ååã«éããŠã¹ïŒå¹³å
äœé18ã20gïŒïŒçŸ€ã«ãããŠïŒã«è ¹è å æäžã
ãããã®åŸã15ååŸã«ããŠã¹ãé éšæ£çž®ã«é¢ããŠ
芳å¯ãããã€ãã®çµæãID50å€ãšããŠè¡šãããäŸ
ãã°é®éã«ããå¿çã®ç¹ç°çæå¶ã¯ãè³ã®è§ŠèŠç
åºæ¿ã«å¯Ÿããè³ç¿Œåå°ã®ååšåã¯äžååšã®æž¬å®ã«
ããã°æé€ãããŠããªãã
(3) ã©ããã«ãããŠããšã³ãã«ã©ãã³ã«ããèªçº
ãããéæž©çã®æ®æäœçš ããã¯ãå çããŠãŒãã³è²¯èµéšããïŒâHTã
æŸåºããããšã³ãã«ã©ãã³ã®äœçšã«åºã¥ããŠãã
ææãªçäœå è©Šéšã§ããã
ãããéæž©çã®æ®æäœçš ããã¯ãå çããŠãŒãã³è²¯èµéšããïŒâHTã
æŸåºããããšã³ãã«ã©ãã³ã®äœçšã«åºã¥ããŠãã
ææãªçäœå è©Šéšã§ããã
éã©ããïŒAlderley Park StrainïŒ180ã
220gïŒãé åãããè©Šéšã®éå§ïŒæéåã«æ¯èŒ
çæãç°å¢ïŒ25ã28âïŒã«çœ®ãïŒïŒã±ãŒãžåœãïŒ
å¹ïŒãé åæéãçµäºãããšãã«ååç©ã®çŽè žæž©
床ã枬ããã€ãã®æž©åºŠããã¹ãŠã®å€åãç®å®ãã
ãå¯Ÿç §è¡šç€ºãšããŠå©çšãããå¯Ÿç §æž©åºŠã®èšé²ïŒïŒ
æéåïŒã®ããã«è©Šéšååç©ãåã¯è³Šåœ¢å€ïŒèžç
æ°ŽïŒãçµå£çã«åã¯ç®äžã«æäžãããã®ïŒæéåŸ
ïŒïŒæéïŒã«åã©ããã®çŽè žæž©åºŠã枬å®ãããçš
é15mgïŒKgã®ããšã³ãã«ã©ãã³åã¯èžçæ°ŽïŒå¯Ÿ
ç §ïŒãè ¹è å ã«æ³šå ¥ãããããšã³ãã«ã©ãã³åã¯
èžçæ°ŽãæäžããŠæ¬¡ã®æéåŸã«çŽè žæž©åºŠã枬å®ã
ãïŒ 30åãïŒïŒïŒïŒïŒïŒïŒïŒïŒåã³ïŒæéåŸã
220gïŒãé åãããè©Šéšã®éå§ïŒæéåã«æ¯èŒ
çæãç°å¢ïŒ25ã28âïŒã«çœ®ãïŒïŒã±ãŒãžåœãïŒ
å¹ïŒãé åæéãçµäºãããšãã«ååç©ã®çŽè žæž©
床ã枬ããã€ãã®æž©åºŠããã¹ãŠã®å€åãç®å®ãã
ãå¯Ÿç §è¡šç€ºãšããŠå©çšãããå¯Ÿç §æž©åºŠã®èšé²ïŒïŒ
æéåïŒã®ããã«è©Šéšååç©ãåã¯è³Šåœ¢å€ïŒèžç
æ°ŽïŒãçµå£çã«åã¯ç®äžã«æäžãããã®ïŒæéåŸ
ïŒïŒæéïŒã«åã©ããã®çŽè žæž©åºŠã枬å®ãããçš
é15mgïŒKgã®ããšã³ãã«ã©ãã³åã¯èžçæ°ŽïŒå¯Ÿ
ç §ïŒãè ¹è å ã«æ³šå ¥ãããããšã³ãã«ã©ãã³åã¯
èžçæ°ŽãæäžããŠæ¬¡ã®æéåŸã«çŽè žæž©åºŠã枬å®ã
ãïŒ 30åãïŒïŒïŒïŒïŒïŒïŒïŒïŒåã³ïŒæéåŸã
ãã®è©Šéšã«ãããæ¬ååç©ã®äœçšå¹æãID50å€
ãšããŠãã€ãŸãããšã³ãã«ã©ãã³ã®æšæºçšéã«å¯Ÿ
ããéæž©çã®å¿çã50ïŒ äœäžãããæ¬ååç©ã®çš
éãšããŠè¡šããã
ãšããŠãã€ãŸãããšã³ãã«ã©ãã³ã®æšæºçšéã«å¯Ÿ
ããéæž©çã®å¿çã50ïŒ äœäžãããæ¬ååç©ã®çš
éãšããŠè¡šããã
æ¬çºæã®ç¹ç°çååç©ã®äœçšæ§ã¯å³å¯ãªååŠç
æ§é ã«çžå¿ããããäžè¬çã«ã¯æ¬çºæã®ååç©ã¯
åèšã®è©Šéšã«ãããŠå¹åã次ã®ç¯å²ã§åããïŒ è©Šéš(1)(a)ïŒã3Hã5HTçµåïŒpI505ãïŒ è©Šéš(1)(b)ïŒã3Hãã¹ããããªããŒã«çµåïŒpI505
ãïŒ è©Šéš(2) ïŒID500.1ã50mgïŒKg è©Šéš(3) ïŒID500.1ã50mgïŒKg æ¯æ§äœçšåã¯ä»ã®äžææãªäœçšã¯åèšã®è©Šéšã§
掻æ§ã§ããçšéã®ååç©ãçšããŠãèŠãããªãã€
ããæŽã«ãæ¬çºæã®ç¹ç°çååç©ã®æ¯æ§ãäœãã
ãšã瀺ããã®ãšããŠãïŒâïŒïŒâãžã¡ãã«ã¢ãã
ãšããã·ïŒâïŒâããšãã«ãããªã³ãããã¯ããª
ããäžæ¢ç¥çµç³»è©Šéšã®ãã«ãã»ãªãã¶ãã€ã·ãšã
ã«ã»ããããªïŒmultiâobservational batteryïŒ
ã«ãããŠããŠã¹ã§è©Šéšãããæçœãªæ¯æ§ã¯çµå£çš
é100mgïŒKgãŸã§èŠãããªãã€ãã
æ§é ã«çžå¿ããããäžè¬çã«ã¯æ¬çºæã®ååç©ã¯
åèšã®è©Šéšã«ãããŠå¹åã次ã®ç¯å²ã§åããïŒ è©Šéš(1)(a)ïŒã3Hã5HTçµåïŒpI505ãïŒ è©Šéš(1)(b)ïŒã3Hãã¹ããããªããŒã«çµåïŒpI505
ãïŒ è©Šéš(2) ïŒID500.1ã50mgïŒKg è©Šéš(3) ïŒID500.1ã50mgïŒKg æ¯æ§äœçšåã¯ä»ã®äžææãªäœçšã¯åèšã®è©Šéšã§
掻æ§ã§ããçšéã®ååç©ãçšããŠãèŠãããªãã€
ããæŽã«ãæ¬çºæã®ç¹ç°çååç©ã®æ¯æ§ãäœãã
ãšã瀺ããã®ãšããŠãïŒâïŒïŒâãžã¡ãã«ã¢ãã
ãšããã·ïŒâïŒâããšãã«ãããªã³ãããã¯ããª
ããäžæ¢ç¥çµç³»è©Šéšã®ãã«ãã»ãªãã¶ãã€ã·ãšã
ã«ã»ããããªïŒmultiâobservational batteryïŒ
ã«ãããŠããŠã¹ã§è©Šéšãããæçœãªæ¯æ§ã¯çµå£çš
é100mgïŒKgãŸã§èŠãããªãã€ãã
ïŒâHTæ®æ質ãšããŠäœçšããã®ã§ãæ¬çºæã«
ããååç©ã¯ããã«ãããŠèšåºçã«äžæ¢ç¥çµç³»ã®
çŸæ£åã¯æ©èœé害ãæ²»çããå粟ç¥å€ãšããŠäŸã
ã°ç²Ÿç¥ç ã粟ç¥åè£ç ãèºç ãäžå®åã¯æãã€ç
ã®æ²»çãçé çããããŸç¹ãåæ¯ãé«è¡å§çãèº
埪ç°æå§ãè¡ç®¡ççž®åã³èè žçŸæ£ã®æ²»çåã³è¡å°
æ¿ååºã®é»æ¢ã«äœ¿çšããããšãã§ãããæ¬ååç©
ã®ïŒã€ãæ£è ã«èšåºçã«äœ¿çšããå Žåã«ã次ã®çš
éã§æäžããããšãæšå¥šãããïŒ (a) çµå£çã«é©åœãªééãäŸãã°ïŒæ¥åœãïŒåçš
é0.5ã100mgïŒKg㧠å㯠(b) çèå ã«å¥œé©ãªééã§çšé0.1ã20mgïŒKg㧠å㯠(c) ãããŒæ³šå°ã«ããã2.5ã100mgïŒKg㧠å㯠(d) çŽè žã«çšé0.5ã200mgïŒKg㧠æŽã«ãæ¬çºæã«ããïŒâïŒïŒâãžã¡ãã«ã¢ãã
ãšããã·ïŒâïŒâããšãã«ãããªã³åã¯ãã®è£œè¬
åŠçã«èš±å®¹ãããé žä»å å¡©ãé€ããŠããR1ã
R2åã³R3ãåèšã®ãã®ãè¡šããåŒã®ååç©å
ã¯ãã®è£œè¬çã«èš±å®¹ãããé žä»å å¡©åã³è£œè¬åŠç
ã«èš±å®¹ãããäžæŽ»æ§ãªçšéå€åã¯è³Šåœ¢å€ãå«æã
ã補è¬åŠççµæç©ãåŸãããã
ããååç©ã¯ããã«ãããŠèšåºçã«äžæ¢ç¥çµç³»ã®
çŸæ£åã¯æ©èœé害ãæ²»çããå粟ç¥å€ãšããŠäŸã
ã°ç²Ÿç¥ç ã粟ç¥åè£ç ãèºç ãäžå®åã¯æãã€ç
ã®æ²»çãçé çããããŸç¹ãåæ¯ãé«è¡å§çãèº
埪ç°æå§ãè¡ç®¡ççž®åã³èè žçŸæ£ã®æ²»çåã³è¡å°
æ¿ååºã®é»æ¢ã«äœ¿çšããããšãã§ãããæ¬ååç©
ã®ïŒã€ãæ£è ã«èšåºçã«äœ¿çšããå Žåã«ã次ã®çš
éã§æäžããããšãæšå¥šãããïŒ (a) çµå£çã«é©åœãªééãäŸãã°ïŒæ¥åœãïŒåçš
é0.5ã100mgïŒKg㧠å㯠(b) çèå ã«å¥œé©ãªééã§çšé0.1ã20mgïŒKg㧠å㯠(c) ãããŒæ³šå°ã«ããã2.5ã100mgïŒKg㧠å㯠(d) çŽè žã«çšé0.5ã200mgïŒKg㧠æŽã«ãæ¬çºæã«ããïŒâïŒïŒâãžã¡ãã«ã¢ãã
ãšããã·ïŒâïŒâããšãã«ãããªã³åã¯ãã®è£œè¬
åŠçã«èš±å®¹ãããé žä»å å¡©ãé€ããŠããR1ã
R2åã³R3ãåèšã®ãã®ãè¡šããåŒã®ååç©å
ã¯ãã®è£œè¬çã«èš±å®¹ãããé žä»å å¡©åã³è£œè¬åŠç
ã«èš±å®¹ãããäžæŽ»æ§ãªçšéå€åã¯è³Šåœ¢å€ãå«æã
ã補è¬åŠççµæç©ãåŸãããã
æ¬çºæã®è£œè¬ççµæç©ã¯çµå£çãè
žç®¡å€åã¯çŽ
è žæäžã«å¥œé©ãªåœ¢ç¶ã§ãã€ãŠãããããæ ãäŸã
ã°çµå£æäžå¯èœãªåäœçšé圢ãäŸãã°å Žåã«ãã
æç¶çãªæŸåºã«é©åãããããšã®ã§ããé å€åã¯
ã«ãã»ã«å€ã泚å°å¯èœãªåœ¢ç¶ãäŸãã°æ» èãã泚
å°å¯èœãªæº¶æ¶²åã¯æžæ¿æ¶²ããããã¯çŽè žæäžåœ¢ã®
åå€ã§ãã€ãŠããããã®è£œè¬ççµæç©ã¯åžžçšã®çš
éå€åã³è³Šåœ¢å€ã䜿çšããåžžæ³ã§çæããããšã
ã§ããã
è žæäžã«å¥œé©ãªåœ¢ç¶ã§ãã€ãŠãããããæ ãäŸã
ã°çµå£æäžå¯èœãªåäœçšé圢ãäŸãã°å Žåã«ãã
æç¶çãªæŸåºã«é©åãããããšã®ã§ããé å€åã¯
ã«ãã»ã«å€ã泚å°å¯èœãªåœ¢ç¶ãäŸãã°æ» èãã泚
å°å¯èœãªæº¶æ¶²åã¯æžæ¿æ¶²ããããã¯çŽè žæäžåœ¢ã®
åå€ã§ãã€ãŠããããã®è£œè¬ççµæç©ã¯åžžçšã®çš
éå€åã³è³Šåœ¢å€ã䜿çšããåžžæ³ã§çæããããšã
ã§ããã
æ¬çºæã®è£œè¬åŠççµæç©ã¯ããR1ãR2åã³
R3ãåèšã®ãã®ãè¡šããåŒã®ååç©åã¯ãã®
補è¬åŠçã«èš±å®¹ãããé žä»å å¡©ãšå ±ã«æ¬¡ã®å»è¬ïŒ
皮以äžãå«æããŠããïŒ ïŒ å ¬ç¥ã®å粟ç¥å€ãäŸãã°æ粟ç¥ç è¬ãäŸãã°
ã¯ãã«ããããžã³ãããããªããŒã«åã¯ãã«ã
ãšããžã³ããããã¯ææãã€å€ãäŸãã°ã€ãã
ã©ãã³ããã¢ã³ã»ãªã³åã¯ãã¹ã¡ãã©ãããªã
ããªã³ïŒ ïŒ å ¬ç¥ã®æçé çå€ãäŸãã°ãšã«ãŽããã¢ã«ã«
ãã€ãåã³ãã®èªå°äœãåã³ãããã©ãããŒ
ã«ãã¯ãããžã³ããããªãããšã³ãïœâã¢ã»ã
ã«ãµãªãã«é žåã¯ãã©ã»ã¿ã¢ãŒã«ïŒ ïŒ éå§å€ãäŸãã°Î±âã¡ãã«ããŒããαâã¢ã
ã¬ããªã³äœåæ§å¹æé®æè¬ãäŸãã°ãã©ãŸã
ã³ãβâã¢ãã¬ããªã³äœåæ§å¹æé®æè¬ãäŸã
ã°ãããã©ãããŒã«åã¯ã¢ããããŒã«ãå©å°¿
å€ãäŸãã°ãããã¯ãããã¢ãžãåã¯ãã«ã»ã
ããåã³è¡ç®¡æ¡åŒµå€ãäŸãã°ãããã·ãžã«åã¯
ããã©ã©ãžã³ïŒ ïŒ å ¬ç¥ã®è¡å°æ¿ååºé»æ¢å€ãäŸãã°ãžããªãã¢
ãŒã«ãã¢ã³ããŠã©ã³ãã¹ã«ãã€ã³ãã©ãŸã³ãã
ã¯ãããžã³åã³ïœâã¢ã»ãã«ãµãªãã«é žã
R3ãåèšã®ãã®ãè¡šããåŒã®ååç©åã¯ãã®
補è¬åŠçã«èš±å®¹ãããé žä»å å¡©ãšå ±ã«æ¬¡ã®å»è¬ïŒ
皮以äžãå«æããŠããïŒ ïŒ å ¬ç¥ã®å粟ç¥å€ãäŸãã°æ粟ç¥ç è¬ãäŸãã°
ã¯ãã«ããããžã³ãããããªããŒã«åã¯ãã«ã
ãšããžã³ããããã¯ææãã€å€ãäŸãã°ã€ãã
ã©ãã³ããã¢ã³ã»ãªã³åã¯ãã¹ã¡ãã©ãããªã
ããªã³ïŒ ïŒ å ¬ç¥ã®æçé çå€ãäŸãã°ãšã«ãŽããã¢ã«ã«
ãã€ãåã³ãã®èªå°äœãåã³ãããã©ãããŒ
ã«ãã¯ãããžã³ããããªãããšã³ãïœâã¢ã»ã
ã«ãµãªãã«é žåã¯ãã©ã»ã¿ã¢ãŒã«ïŒ ïŒ éå§å€ãäŸãã°Î±âã¡ãã«ããŒããαâã¢ã
ã¬ããªã³äœåæ§å¹æé®æè¬ãäŸãã°ãã©ãŸã
ã³ãβâã¢ãã¬ããªã³äœåæ§å¹æé®æè¬ãäŸã
ã°ãããã©ãããŒã«åã¯ã¢ããããŒã«ãå©å°¿
å€ãäŸãã°ãããã¯ãããã¢ãžãåã¯ãã«ã»ã
ããåã³è¡ç®¡æ¡åŒµå€ãäŸãã°ãããã·ãžã«åã¯
ããã©ã©ãžã³ïŒ ïŒ å ¬ç¥ã®è¡å°æ¿ååºé»æ¢å€ãäŸãã°ãžããªãã¢
ãŒã«ãã¢ã³ããŠã©ã³ãã¹ã«ãã€ã³ãã©ãŸã³ãã
ã¯ãããžã³åã³ïœâã¢ã»ãã«ãµãªãã«é žã
次ã«æ¬çºæãå®æœäŸã«ãã詳説ãããã枩床ã¯
ã»ãæ°ã§ãããã€ç³æ²¹ãšãŒãã«ã¯æ²žç¹60ã80âã
æããŠããã
ã»ãæ°ã§ãããã€ç³æ²¹ãšãŒãã«ã¯æ²žç¹60ã80âã
æããŠããã
äŸ ïŒ
ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«ïŒ1.07gïŒããž
ã¡ãã«ãã«ã ã¢ããïŒ25mlïŒäžã®æ°ŽçŽ åãããªãŠ
ã ïŒé±æ²¹äžã®50ïŒ ïœïŒïœâåæ£æ¶²0.56gïŒã®æžæ¿
液ã«ïŒã5ãã§æ»Žå ãããå šæ°ŽçŽ ãçºçãããïŒâ
ã¯ããâïŒâããšãã«ãããªã³ïŒ2.5gïŒãæ·»å ã
ãã€æ··åç©ãæ¹æããã€75âã§12æéå ç±ããã
ãã®åŸãæ··åç©ãåšå²æž©åºŠã«å·åŽããæ°·æ°ŽïŒ500
mlïŒäžã«æ³šããã€é ¢é žãšãã«ïŒïŒÃ100mlïŒã§æœ
åºãããé ¢é žãšãã«æœåºç©ãé£ç¶çã«æ°ŽïŒ50mlïŒ
åã³é£œåãã©ã€ã³ïŒ50mlïŒã§æŽãã也ç¥ããã
ïŒMgSO4ïŒã溶å€ãæžå§äžïŒçŽ15mmHgïŒã«èžçºã
ããã€æ®çæ²¹ç¶ç©ãå¡©åºæ§ã¢ã«ããïŒ100gãã
ããã¯ãã³ã»ã°ã¬ãŒãïŒäžã§ãå¢å ããæ¿åºŠã®
ç³æ²¹ãšãŒãã«äžã®ã¯ãããã«ã ãçšããŠæº¶é¢ããŠ
ã¯ãããã°ã©ãã€åŠçãããç³æ²¹ãšãŒãã«äžã®10
ïŒ ïœïŒïœâã¯ãããã«ã ã§åŸããã溶åºæ¶²ãèžçº
ããããæ®çæ²¹ç¶ç©ããžãšãã«ãšãŒãã«ïŒ100mlïŒ
äžã«æº¶è§£ããã€ãšãŒãã«æ§å¡©åæ°ŽçŽ ãæ²æ®¿ãå®çµ
ãããŸã§å ãããæ··åç©ãæ¿Ÿéããã€åºäœæ®æž£ã
ãšã¿ããŒã«ïŒãžãšãã«ãšãŒãã«ããçµæ¶ããããš
ïŒâïŒïŒâãžã¡ãã«ã¢ãããšããã·ïŒâïŒâããšã
ã«ãããªã³ãããã¯ããªãïŒèç¹155ã157ãïŒã
åŸãããã
ã¡ãã«ãã«ã ã¢ããïŒ25mlïŒäžã®æ°ŽçŽ åãããªãŠ
ã ïŒé±æ²¹äžã®50ïŒ ïœïŒïœâåæ£æ¶²0.56gïŒã®æžæ¿
液ã«ïŒã5ãã§æ»Žå ãããå šæ°ŽçŽ ãçºçãããïŒâ
ã¯ããâïŒâããšãã«ãããªã³ïŒ2.5gïŒãæ·»å ã
ãã€æ··åç©ãæ¹æããã€75âã§12æéå ç±ããã
ãã®åŸãæ··åç©ãåšå²æž©åºŠã«å·åŽããæ°·æ°ŽïŒ500
mlïŒäžã«æ³šããã€é ¢é žãšãã«ïŒïŒÃ100mlïŒã§æœ
åºãããé ¢é žãšãã«æœåºç©ãé£ç¶çã«æ°ŽïŒ50mlïŒ
åã³é£œåãã©ã€ã³ïŒ50mlïŒã§æŽãã也ç¥ããã
ïŒMgSO4ïŒã溶å€ãæžå§äžïŒçŽ15mmHgïŒã«èžçºã
ããã€æ®çæ²¹ç¶ç©ãå¡©åºæ§ã¢ã«ããïŒ100gãã
ããã¯ãã³ã»ã°ã¬ãŒãïŒäžã§ãå¢å ããæ¿åºŠã®
ç³æ²¹ãšãŒãã«äžã®ã¯ãããã«ã ãçšããŠæº¶é¢ããŠ
ã¯ãããã°ã©ãã€åŠçãããç³æ²¹ãšãŒãã«äžã®10
ïŒ ïœïŒïœâã¯ãããã«ã ã§åŸããã溶åºæ¶²ãèžçº
ããããæ®çæ²¹ç¶ç©ããžãšãã«ãšãŒãã«ïŒ100mlïŒ
äžã«æº¶è§£ããã€ãšãŒãã«æ§å¡©åæ°ŽçŽ ãæ²æ®¿ãå®çµ
ãããŸã§å ãããæ··åç©ãæ¿Ÿéããã€åºäœæ®æž£ã
ãšã¿ããŒã«ïŒãžãšãã«ãšãŒãã«ããçµæ¶ããããš
ïŒâïŒïŒâãžã¡ãã«ã¢ãããšããã·ïŒâïŒâããšã
ã«ãããªã³ãããã¯ããªãïŒèç¹155ã157ãïŒã
åŸãããã
äŸ ïŒ
ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«ïŒ1.07gïŒããž
ã¡ãã«ãã«ã ã¢ããïŒ25mlïŒäžã®æ°ŽçŽ åãããªãŠ
ã ïŒé±æ²¹äžã®50ïŒ ïœïŒïœâåæ£æ¶²0.56gïŒã®æžæ¿
液ã«ïŒã5ãã§æ»Žå ãããå šæ°ŽçŽ ãçºçãããšãã«
ïŒâã¯ããâïŒâïŒïŒâãã«ãªãããšãã«ïŒãã
ãªã³ïŒ2.69gïŒãå ããã€æ··åç©ãåšå²æž©åºŠã§16
æéæ¹æããããã®åŸãæ··åç©ãæ°·æ°ŽïŒ500mlïŒ
äžã«æ³šããã€é ¢é žãšãã«ïŒïŒÃ100mlïŒã§æœåºã
ããé ¢é žãšãã«æœåºç©ãé£ç¶çã«æ°ŽïŒ50mlïŒåã³
飜åãã©ã€ã³ïŒ50mlïŒã§æŽãã也ç¥ããã
ïŒMgSO4ïŒã溶å€ãæžå§äžã«èžçºãããã€æ®çæ²¹
ç¶ç©ãå¡©åºæ§ã¢ã«ããïŒ100gããããã¯ãã³ã»
ã°ã¬ãŒãïŒäžã§ãå¢å ããæ¿åºŠã®ç³æ²¹ãšãŒãã«
äžã®é ¢é žãšãã«ã§æº¶é¢ããŠã¯ãããã°ã©ãã€åŠç
ãããç³æ²¹ãšãŒãã«äžã®10ïŒ ïœïŒïœâé ¢é žãšãã«
ã§åŸããã溶åºæ¶²ãèžçºããããæ®çæ²¹ç¶ç©ã¯ãž
ãšãã«ãšãŒãã«ïŒ100mlïŒäžã«æº¶è§£ããã€ãšãŒã
ã«æ§å¡©åæ°ŽçŽ ãæ²æ®¿ãå®çµãããŸã§å ãããæ··å
ç©ãæ¿Ÿéããã€åºäœæ®æž£ãã¡ã¿ããŒã«ïŒé ¢é žãšã
ã«ããçµæ¶ãããŠïŒâïŒïŒâãžã¡ãã«ã¢ãããšã
ãã·ïŒâïŒâïŒïŒâãã«ãªã«ããšãã«ïŒãããªã³ã
ããã¯ããªãïŒèç¹168ã171ãïŒãçæããã
ã¡ãã«ãã«ã ã¢ããïŒ25mlïŒäžã®æ°ŽçŽ åãããªãŠ
ã ïŒé±æ²¹äžã®50ïŒ ïœïŒïœâåæ£æ¶²0.56gïŒã®æžæ¿
液ã«ïŒã5ãã§æ»Žå ãããå šæ°ŽçŽ ãçºçãããšãã«
ïŒâã¯ããâïŒâïŒïŒâãã«ãªãããšãã«ïŒãã
ãªã³ïŒ2.69gïŒãå ããã€æ··åç©ãåšå²æž©åºŠã§16
æéæ¹æããããã®åŸãæ··åç©ãæ°·æ°ŽïŒ500mlïŒ
äžã«æ³šããã€é ¢é žãšãã«ïŒïŒÃ100mlïŒã§æœåºã
ããé ¢é žãšãã«æœåºç©ãé£ç¶çã«æ°ŽïŒ50mlïŒåã³
飜åãã©ã€ã³ïŒ50mlïŒã§æŽãã也ç¥ããã
ïŒMgSO4ïŒã溶å€ãæžå§äžã«èžçºãããã€æ®çæ²¹
ç¶ç©ãå¡©åºæ§ã¢ã«ããïŒ100gããããã¯ãã³ã»
ã°ã¬ãŒãïŒäžã§ãå¢å ããæ¿åºŠã®ç³æ²¹ãšãŒãã«
äžã®é ¢é žãšãã«ã§æº¶é¢ããŠã¯ãããã°ã©ãã€åŠç
ãããç³æ²¹ãšãŒãã«äžã®10ïŒ ïœïŒïœâé ¢é žãšãã«
ã§åŸããã溶åºæ¶²ãèžçºããããæ®çæ²¹ç¶ç©ã¯ãž
ãšãã«ãšãŒãã«ïŒ100mlïŒäžã«æº¶è§£ããã€ãšãŒã
ã«æ§å¡©åæ°ŽçŽ ãæ²æ®¿ãå®çµãããŸã§å ãããæ··å
ç©ãæ¿Ÿéããã€åºäœæ®æž£ãã¡ã¿ããŒã«ïŒé ¢é žãšã
ã«ããçµæ¶ãããŠïŒâïŒïŒâãžã¡ãã«ã¢ãããšã
ãã·ïŒâïŒâïŒïŒâãã«ãªã«ããšãã«ïŒãããªã³ã
ããã¯ããªãïŒèç¹168ã171ãïŒãçæããã
äŸ ïŒãïŒ
äŸïŒã«èšèŒããæ¹æ³ã次ã®åºçºç©è³ªãèšèŒãã
éã§äœ¿çšããŠç¹°è¿ããŠæ¬¡ã®ãã®ãåŸãããïŒ ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«ïŒ1.07gïŒåã³
ïŒâã¯ããâïŒâïŒïŒâã¡ããã·ããšãã«ïŒãã
ãªã³2.81gããèç¹130ã132ãã®ïŒâïŒïŒâãžã¡ã
ã«ã¢ãããšããã·ïŒâïŒâïŒïŒâã¡ããã·ããšã
ã«ïŒãããªã³ãããã¯ããªãïŒäŸïŒïŒïŒ ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«ïŒ1.07gïŒåã³
ïŒâã¯ããâïŒâã€ãœãããã«ãããªã³ïŒ2.27gïŒ
ããèç¹167ã171ãã®ïŒâïŒïŒâãžã¡ãã«ã¢ãããš
ããã·ïŒâïŒâã€ãœãããã«ãããªã³ãããã¯ã
ãªãïŒäŸïŒïŒïŒ ïŒâãžã¡ãã«ã¢ããâïŒâã¡ãã«ãããããŒã«
ïŒ1.41gïŒåã³ïŒâã¯ããâïŒâããšãã«ãããªã³
ïŒ2.5gïŒããèç¹183ã184ãã®ïŒâïŒïŒâãžã¡ãã«
ã¢ããâïŒâã¡ãã«ããããã·ïŒâïŒâããšãã«
ãããªã³ãããã¯ããªãïŒäŸïŒïŒã
éã§äœ¿çšããŠç¹°è¿ããŠæ¬¡ã®ãã®ãåŸãããïŒ ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«ïŒ1.07gïŒåã³
ïŒâã¯ããâïŒâïŒïŒâã¡ããã·ããšãã«ïŒãã
ãªã³2.81gããèç¹130ã132ãã®ïŒâïŒïŒâãžã¡ã
ã«ã¢ãããšããã·ïŒâïŒâïŒïŒâã¡ããã·ããšã
ã«ïŒãããªã³ãããã¯ããªãïŒäŸïŒïŒïŒ ïŒâãžã¡ãã«ã¢ãããšã¿ããŒã«ïŒ1.07gïŒåã³
ïŒâã¯ããâïŒâã€ãœãããã«ãããªã³ïŒ2.27gïŒ
ããèç¹167ã171ãã®ïŒâïŒïŒâãžã¡ãã«ã¢ãããš
ããã·ïŒâïŒâã€ãœãããã«ãããªã³ãããã¯ã
ãªãïŒäŸïŒïŒïŒ ïŒâãžã¡ãã«ã¢ããâïŒâã¡ãã«ãããããŒã«
ïŒ1.41gïŒåã³ïŒâã¯ããâïŒâããšãã«ãããªã³
ïŒ2.5gïŒããèç¹183ã184ãã®ïŒâïŒïŒâãžã¡ãã«
ã¢ããâïŒâã¡ãã«ããããã·ïŒâïŒâããšãã«
ãããªã³ãããã¯ããªãïŒäŸïŒïŒã
äŸ ïŒ
äŸïŒã«èšèŒã®æ¹æ³ãç¹°è¿ããããäœãïŒâãžã¡
ãã«ã¢ãããšã¿ããŒã«åã³ïŒâã¯ããâïŒâïŒïŒ
âãã«ãªãããšãã«ïŒãããªã³ã®ä»£ãã«åºçºç©è³ª
ã¯ïŒâãžã¡ãã«ã¢ãããããããŒã«ïŒ1.24gïŒå
ã³ïŒâã¯ããâïŒâããšãã«ãããªã³ïŒ2.5gïŒã§
ãããã¯ãããã°ã©ãã€ã§äœ¿çšãã溶é¢å€ã¯å¢å
ããæ¿åºŠã®ç³æ²¹ãšãŒãã«äžã®é ¢é žãšãã«ã®ä»£ãã«
ç³æ²¹ãšãŒãã«ã§ãã€ãããã®ããã«ããŠãèç¹
184ã186âã®ïŒâïŒïŒâãžã¡ãã«ã¢ãããããã
ã·ïŒâïŒâããšãã«ãããªã³ãããã¯ããªããåŸ
ãããã
ãã«ã¢ãããšã¿ããŒã«åã³ïŒâã¯ããâïŒâïŒïŒ
âãã«ãªãããšãã«ïŒãããªã³ã®ä»£ãã«åºçºç©è³ª
ã¯ïŒâãžã¡ãã«ã¢ãããããããŒã«ïŒ1.24gïŒå
ã³ïŒâã¯ããâïŒâããšãã«ãããªã³ïŒ2.5gïŒã§
ãããã¯ãããã°ã©ãã€ã§äœ¿çšãã溶é¢å€ã¯å¢å
ããæ¿åºŠã®ç³æ²¹ãšãŒãã«äžã®é ¢é žãšãã«ã®ä»£ãã«
ç³æ²¹ãšãŒãã«ã§ãã€ãããã®ããã«ããŠãèç¹
184ã186âã®ïŒâïŒïŒâãžã¡ãã«ã¢ãããããã
ã·ïŒâïŒâããšãã«ãããªã³ãããã¯ããªããåŸ
ãããã
äŸ ïŒ
æ°ŽçŽ åãããªãŠã ïŒé±æ²¹äžã®50ïŒ
ïœïŒïœâåæ£
液0.48gïŒããžã¡ãã«ãã«ã ã¢ããïŒ20mlïŒäžã®
ïŒâãžã¡ãã«ã¢ãããããããŒã«ïŒ1.1gïŒã®æº¶æ¶²
ã«åšå²æž©åºŠã§å ãããå šæ°ŽçŽ ãçºçãããïŒâã¯
ããâïŒâããšãã«ãããªã³ïŒ2.4gïŒãå ããã€
æ··åç©ãåšå²æž©åºŠã§16æéæ¹æãããæ··åç©ãæ°Ž
ïŒ200mlïŒäžã«æ³šããã€é ¢é žãšãã«ïŒïŒÃ100mlïŒ
ã§æœåºãããé ¢é žãšãã«æœåºç©ãæ°ŽïŒ50mlïŒã§æŽ
ãã也ç¥ãããïŒMgSO4ïŒæº¶å€ãæžå§äžã«èžçº
ãããã€æ®çæ²¹ç¶ç©ãå¡©åºæ§ã¢ã«ããïŒ100gã
ãããã¯ãã³ã»ã°ã¬ãŒãïŒäžãå¢å ããæ¿åºŠã®
ç³æ²¹ãšãŒãã«äžã®ã¯ãããã«ã ã§æº¶é¢ããŠã¯ãã
ãã°ã©ãã€åŠçãããç³æ²¹ãšãŒãã«äžã®20ïŒ ïœïŒ
ïœâã¯ãããã«ã ã§åŸããã溶åºæ¶²ãèžçºãã
ããæ®çæ²¹ç¶ç©ããžãšãã«ãšãŒãã«ïŒ50mlïŒäžã«
溶解ãããšãŒãã«æ§å¡©åæ°ŽçŽ ãæ²æ®¿ãå®çµãããŸ
ã§å ãããæ··åç©ãæ¿Ÿéããã€åºäœæ®æž£ãé ¢é žãš
ãã«ïŒãžãšãã«ãšãŒãã«ããæ²æ®¿ããããšïŒâ
ïŒïŒâãžã¡ãã«ã¢ããããããã·ïŒâïŒâããšãã«
ãããªã³ãããã¯ããªããçæãããïœïŒz305
ãïŒïŒâïŒ+ïŒC20H21N2Oã®èšç®å€305.1654ãå®æž¬
å€305.1654ãã
液0.48gïŒããžã¡ãã«ãã«ã ã¢ããïŒ20mlïŒäžã®
ïŒâãžã¡ãã«ã¢ãããããããŒã«ïŒ1.1gïŒã®æº¶æ¶²
ã«åšå²æž©åºŠã§å ãããå šæ°ŽçŽ ãçºçãããïŒâã¯
ããâïŒâããšãã«ãããªã³ïŒ2.4gïŒãå ããã€
æ··åç©ãåšå²æž©åºŠã§16æéæ¹æãããæ··åç©ãæ°Ž
ïŒ200mlïŒäžã«æ³šããã€é ¢é žãšãã«ïŒïŒÃ100mlïŒ
ã§æœåºãããé ¢é žãšãã«æœåºç©ãæ°ŽïŒ50mlïŒã§æŽ
ãã也ç¥ãããïŒMgSO4ïŒæº¶å€ãæžå§äžã«èžçº
ãããã€æ®çæ²¹ç¶ç©ãå¡©åºæ§ã¢ã«ããïŒ100gã
ãããã¯ãã³ã»ã°ã¬ãŒãïŒäžãå¢å ããæ¿åºŠã®
ç³æ²¹ãšãŒãã«äžã®ã¯ãããã«ã ã§æº¶é¢ããŠã¯ãã
ãã°ã©ãã€åŠçãããç³æ²¹ãšãŒãã«äžã®20ïŒ ïœïŒ
ïœâã¯ãããã«ã ã§åŸããã溶åºæ¶²ãèžçºãã
ããæ®çæ²¹ç¶ç©ããžãšãã«ãšãŒãã«ïŒ50mlïŒäžã«
溶解ãããšãŒãã«æ§å¡©åæ°ŽçŽ ãæ²æ®¿ãå®çµãããŸ
ã§å ãããæ··åç©ãæ¿Ÿéããã€åºäœæ®æž£ãé ¢é žãš
ãã«ïŒãžãšãã«ãšãŒãã«ããæ²æ®¿ããããšïŒâ
ïŒïŒâãžã¡ãã«ã¢ããããããã·ïŒâïŒâããšãã«
ãããªã³ãããã¯ããªããçæãããïœïŒz305
ãïŒïŒâïŒ+ïŒC20H21N2Oã®èšç®å€305.1654ãå®æž¬
å€305.1654ãã
Claims (1)
- ãç¹èš±è«æ±ã®ç¯å²ã ïŒ ïŒâïŒïŒâãžãšãã«ã¢ãããšããã·ïŒâïŒâã
ãšãã«ãããªã³åã³ãã®è£œè¬åŠçã«èš±å®¹ãããé ž
ä»å å¡©ãé€ããŠãåŒïŒ ãåŒäž ã¯ã¡ãã«åºïŒåã¯ïŒåã«ãã眮æãããŠããŠ
ãããâïŒCH2ïŒ2âåºãåã¯âïŒCH2ïŒ3âåºãè¡šã
ãã R1ã¯ïœâãã€ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºã
ã·ã¯ããããã«åºãåã¯ããã²ã³åååã¯C1ã4â
ã¢ã«ã³ãã·åºã«ãã眮æãããŠããŠãããããšã
ã«åºãè¡šããã R2åã³R3ã¯åããåã¯ç°ãªã€ãŠãããã¡ãã«
åºåã¯ãšãã«åºãè¡šãããã®ãããªã³èªå°äœåã¯
ãã®è£œè¬åŠçã«èš±å®¹ãããé žä»å å¡©ã ïŒ ïŒ¡ãïŒïŒïŒâãšãã¬ã³ãïŒïŒïŒâãããã¬
ã³ãïŒïŒïŒâãããã¬ã³ãïŒïŒïŒâãžã¡ãã«â
ïŒïŒïŒâãšãã¬ã³ãïŒïŒïŒâãžã¡ãã«âïŒïŒïŒâ
ãšãã¬ã³åã¯ïŒïŒïŒâãããã¬ã³åºã§ããç¹èš±è«
æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®èªå°äœåã¯ãã®è£œè¬åŠçã«
蚱容ãããé žä»å å¡©ã ïŒ R1ãïœâãããã«ãã€ãœãããã«ãïœâã
ãã«ãïœâããã«ãã·ã¯ããããã«åã¯ããšãã«
åºãããã¯åŒçŽ ãå¡©çŽ åã¯èçŽ ååæãã¯C1ã2â
ã¢ã«ã³ãã·åºã«ãã眮æãããŠããããšãã«åºã§
ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒé èšèŒã®èªå°
äœåã¯ãã®è£œè¬åŠçã«èš±å®¹ãããé žä»å å¡©ã ïŒ ïŒ¡ãã¡ãã«åºïŒåã¯ïŒåã«ãã眮æãããŠã
ãŠãããâïŒCH2ïŒ2âåºãåã¯âïŒCH2ïŒ3âåºãè¡š
ãããR1ã¯ïœâãã€ãœâåã¯ïœâC3ã4âã¢ã«ã
ã«åºãåã¯ããšãã«åºãããã²ã³ããšãã«åã¯
C1ã2âã¢ã«ã³ãã·ããšãã«åºãè¡šãããã€R2å
ã³R3ãã¡ãã«åºãè¡šããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
ã第ïŒé ã®ããããïŒé ã«èšèŒã®èªå°äœåã¯ãã®
補è¬åŠçã«èš±å®¹ãããé žä»å å¡©ã ïŒ ïŒâïŒïŒâãžã¡ãã«ã¢ãããšããã·ïŒâïŒâã
ãšãã«ãããªã³åã¯ãã®è£œè¬åŠçã«èš±å®¹ãããé ž
ä»å å¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé ã第ïŒé ã®ã
ãããïŒé ã«èšèŒã®èªå°äœåã¯ãã®è£œè¬åŠçã«èš±
容ãããé žä»å å¡©ã ïŒ ïŒâïŒïŒâãžãšãã«ã¢ãããšããã·ïŒâïŒâã
ãšãã«ãããªã³åã³ãã®è£œè¬åŠçã«èš±å®¹ãããé ž
ä»å å¡©ãé€ããŠãåŒïŒ ãåŒäž ã¯ã¡ãã«åºïŒåã¯ïŒåã«ãã眮æãããŠããŠ
ãããâïŒCH2ïŒ2âåºåã¯âïŒCH2ïŒ3âåºãè¡šã
ãã R1ã¯ïœâãã€ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºã
ã·ã¯ããããã«åºãåã¯ããã²ã³åååã¯C1ã4â
ã¢ã«ã³ãã·åºã«ãã眮æãããŠããŠãããããšã
ã«åºãè¡šããã R2åã³R3ã¯åããåã¯ç°ãªã€ãŠããŠãããã¡
ãã«åºåã¯ãšãã«åºãè¡šãããã®ãããªã³èªå°äœ
åã¯ãã®è£œè¬åŠçã«èš±å®¹ãããé žä»å å¡©ã補é ã
ãæ¹æ³ã«ãããŠãåŒïŒ ãåŒäžHalã¯ããã²ã³ååãè¡šãããã€R1ã¯å
èšã®ãã®ãè¡šãããã®ååç©ãåŒïŒ HOââNR2R3 ïŒïŒ ãåŒäžïŒ¡ãR2åã³R3ã¯åèšã®ãã®ãè¡šããã
ã®ååç©åã¯ãã®é žä»å å¡©ãšé žçµåå€ã®ååšã«ã
ããŠåå¿ãããããšãç¹åŸŽãšãããããªã³èªå°äœ
ã®è£œæ³ã ïŒ Halãå¡©çŽ åã¯èçŽ ååãè¡šããç¹èš±è«æ±ã®
ç¯å²ç¬¬ïŒé èšèŒã®è£œæ³ã ïŒ é žçµåå€ãæ°ŽçŽ åãããªãŠã ã§ããç¹èš±è«æ±
ã®ç¯å²ç¬¬ïŒé åã¯ç¬¬ïŒé èšèŒã®è£œæ³ã ïŒ ïŒâïŒïŒâãžãšãã«ã¢ãããšããã·ïŒâïŒâã
ãšãã«ãããªã³åã³ãã®è£œè¬åŠçã«èš±å®¹ãããé ž
ä»å å¡©ãé€ããŠãåŒïŒ ãåŒäž ã¯ã¡ãã«åºïŒåã¯ïŒåã«ãã眮æãããŠããŠ
ãããâïŒCH2ïŒ2âåºåã¯âïŒCH2ïŒ3âåºãè¡šã
ãã R1ã¯ïœâãã€ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºã
ã·ã¯ããããã«åºãåã¯ããã²ã³åååã¯C1ã4â
ã¢ã«ã³ãã·åºã«ãã眮æãããŠããŠãããããšã
ã«åºãè¡šããã R2åã³R3ã¯åããåã¯ç°ãªã€ãŠããŠãããã¡
ãã«åºåã¯ãšãã«åºãè¡šãããã®ãããªã³èªå°äœ
åã¯ãã®è£œè¬åŠçã«èš±å®¹ãããé žä»å å¡©ã補é ã
ãæ¹æ³ã«ãããŠãåŒïŒ ãåŒäžHalã¯ããã²ã³ååãè¡šãããã€R1ã¯å
èšã®ãã®ãè¡šãããã®ååç©ãåŒïŒ HOââNR2R3 ïŒïŒ ãåŒäžïŒ¡ãR2åã³R3ã¯åèšã®ãã®ãè¡šããã
ã®ååç©åã¯ãã®é žä»å å¡©ãšé žçµåå€ã®ååšã«ã
ããŠãžã¡ãã«ãã«ã ã¢ããäžã§åå¿ãããããšã
ç¹åŸŽãšãããããªã³èªå°äœã®è£œæ³ã ïŒïŒ ïŒâïŒïŒâãžãšãã«ã¢ãããšããã·ïŒâïŒâ
ããšãã«ãããªã³åã³ãã®è£œè¬åŠçã«èš±å®¹ããã
é žä»å å¡©ãé€ããŠãåŒïŒ ãåŒäž ã¯ã¡ãã«åºïŒåã¯ïŒåã«ãã眮æãããŠããŠ
ãããâïŒCH2ïŒ2âåºãåã¯âïŒCH2ïŒ3âåºãè¡šã
ãã R1ã¯ïœâãã€ãœâåã¯ïœâC3ã4âã¢ã«ãã«åºã
ã·ã¯ããããã«åºãåã¯ããã²ã³åååã¯C1ã4â
ã¢ã«ã³ãã·åºã«ãã眮æãããŠããŠãããããšã
ã«åºãè¡šããã R2åã³R3ã¯åããåã¯ç°ãªã€ãŠããŠãããã¡
ãã«åºåã¯ãšãã«åºãè¡šãããã®ãããªã³èªå°äœ
åã¯ãã®è£œè¬åŠçã«èš±å®¹ãããé žä»å å¡©åã³è£œè¬
åŠçã«èš±å®¹ãããäžæŽ»æ§ãªçšéå€åã¯è³Šåœ¢å€ãå«
æããããšãç¹åŸŽãšãã該èªå°äœãå«æããïŒâ
HTæ®æäœçšãæãã補è¬åŠç補å€ã
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8210261 | 1982-04-07 | ||
GB8210261 | 1982-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS58185564A JPS58185564A (ja) | 1983-10-29 |
JPH0319228B2 true JPH0319228B2 (ja) | 1991-03-14 |
Family
ID=10529572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP58058800A Granted JPS58185564A (ja) | 1982-04-07 | 1983-04-05 | ãããªã³èªå°äœããã®è£œæ³åã³è©²èªå°äœãå«æããïŒâïœïœæ®æäœçšãæãã補è¬åŠçè£œå€ |
Country Status (5)
Country | Link |
---|---|
US (1) | US4607040A (ja) |
EP (1) | EP0091198B1 (ja) |
JP (1) | JPS58185564A (ja) |
AT (1) | ATE27152T1 (ja) |
DE (1) | DE3371511D1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308601D0 (en) * | 1983-03-29 | 1983-05-05 | Ici Plc | Heterocyclic compounds |
DE69016125T2 (de) * | 1989-08-11 | 1995-06-01 | Zeneca Ltd | Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel. |
GB9025123D0 (en) * | 1990-11-19 | 1991-01-02 | Ici Plc | Nitrogen compounds |
US7115399B2 (en) * | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US16394A (en) * | 1857-01-13 | Improvement in gotton-gins | ||
DE430960C (de) * | 1924-07-11 | 1926-06-23 | J G Farbenindustrie Akt Ges | Verfahren zur Darstellung von basischen AEthern von Chinolinderivaten |
US1572768A (en) * | 1925-06-26 | 1926-02-09 | Winthrop Chem Co Inc | Pharmaceutical product |
GB349761A (en) * | 1929-05-16 | 1931-06-04 | Chem Ind Basel | Manufacture of aminoalkoxy-derivatives of aryl-quinolines |
US1860286A (en) * | 1929-05-16 | 1932-05-24 | Soc Of Chemical Ind | Basic ethers of aryl-quinolines |
US4035374A (en) * | 1973-05-03 | 1977-07-12 | Smith Kline & French Laboratories Limited | Imidazolyl alkylaminopyridone and pyridinethione compounds |
US4260764A (en) * | 1976-12-22 | 1981-04-07 | Pfizer Inc. | 9-Hydroxyoctahydrobenzo [C] quinolines and intermediates therefor |
US4343805A (en) * | 1978-12-16 | 1982-08-10 | John Wyeth & Brother Limited | Heterocyclic compounds |
US4235909A (en) * | 1979-04-19 | 1980-11-25 | Eli Lilly And Company | Octahydro-2H-pyrrolo[3,4-g]quinolines |
GR73576B (ja) * | 1980-03-01 | 1984-03-20 | Wyeth John & Brother Ltd | |
IN158970B (ja) * | 1981-06-09 | 1987-02-28 | Ici Plc |
-
1983
- 1983-03-03 AT AT83301137T patent/ATE27152T1/de not_active IP Right Cessation
- 1983-03-03 DE DE8383301137T patent/DE3371511D1/de not_active Expired
- 1983-03-03 EP EP83301137A patent/EP0091198B1/en not_active Expired
- 1983-04-05 JP JP58058800A patent/JPS58185564A/ja active Granted
- 1983-04-06 US US06/482,713 patent/US4607040A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE27152T1 (de) | 1987-05-15 |
EP0091198A3 (en) | 1985-04-17 |
DE3371511D1 (en) | 1987-06-19 |
JPS58185564A (ja) | 1983-10-29 |
EP0091198A2 (en) | 1983-10-12 |
EP0091198B1 (en) | 1987-05-13 |
US4607040A (en) | 1986-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR880002232B1 (ko) | íŽë늰 ì ë첎ì ê·ž ìŒì ì ì¡°ë°©ë² | |
KR0167782B1 (ko) | í ížëŒíëë¡íŒëŠ¬ë ì ë첎 | |
JPH0219112B2 (ja) | ||
AP877A (en) | Tetrahydroquinoline derivatives as EAA antagonists. | |
WO2003013510A1 (en) | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders | |
NZ225706A (en) | 2-((4-piperidyl)methyl)-1,2,3,4-tetrahydro-9h-pyrido(3,4-b) indole derivatives and their preparation | |
SK50895A3 (en) | 3-indolylpiperidine derivative, method of its preparation, its use for preparation of pharmaceutical composition and pharmaceutical composition containing them | |
MXPA02006499A (es) | Derivados de fenilpiperazinilo. | |
EP0066993B1 (en) | Quinoline derivatives | |
EP0093521B1 (en) | Quinoline derivatives | |
JPH0319228B2 (ja) | ||
IL160082A (en) | Quinoline derivatives, pharmaceutical compositions containing them and their use in the preparation of compositions for treating cancer | |
NZ233645A (en) | 3-(hetero)aryl-substituted-3,4 dehydropiperidine derivatives; preparatory processes and pharmaceutical compositions | |
FI71936C (fi) | Foerfarande foer framstaellning av neuroleptiskt aktiva 2-substituerade-8-fluor-5-(4-fluorfenyl)-2,3,4,4a, 5,9b-hexahydro-4a,9b-trans-1h-pyrido/4,3-b/indolderivat. | |
JP2001523679A (ja) | ã€ãããŸãŒã«èªå°äœããã®è£œé ãšæ²»çäžã®çšé | |
EP1053235A1 (en) | Oxazole derivatives as serotonin-1a receptor agonists | |
US4576953A (en) | Quinoline derivatives | |
US6057340A (en) | Oxazole derivatives as serotonin-1A receptor agonists | |
TWI454470B (zh) | ç¡«è¯äžŠèäžé žè¡çç©ä¹è£œé æ³ | |
DK169948B1 (da) | Mellemprodukter til brug ved fremstilling af pyrimido[4,5-g]quinolin-derivater eller salte deraf | |
KR890001149B1 (ko) | íŽë늰 ì ë첎ì ì ì¡°ë°©ë² | |
JPH0429665B2 (ja) | ||
JP2001521536A (ja) | é®ç掻æ§ãæããïŒïŒïŒïŒâãžã¢ã¶ããªã·ã¯ãïŒïŒïŒïŒïŒïŒïŒâ²ïŒïŒïŒâŒïŒœãã«ã³ããã³ïŒïŒïŒïŒâãžã¢ã¶ããªã·ã¯ãïŒïŒïŒïŒïŒïŒïŒâ²ïŒïŒïŒâŒïŒœãã«ã³èªå°äœ | |
JPS6213957B2 (ja) | ||
MXPA05006814A (es) | Atropisomeros de derivados de 4-arilquinolin-2-ona 3-sustituida. |